Knockdown of lncRNA LINC01234 Suppresses the Tumorigenesis of Liver Cancer via Sponging miR-513a-5p.

LINC01234 TGF-β USP4 liver cancer miR-513a-5p

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 11 06 2020
accepted: 21 08 2020
entrez: 12 11 2020
pubmed: 13 11 2020
medline: 13 11 2020
Statut: epublish

Résumé

Liver cancer is a frequent malignancy with poor prognosis and high mortality all over the world. It has been reported many lncRNAs could modulate the tumorigenesis of liver cancer. To identify novel potential targets for liver cancer, the differential expressed lncRNAs between liver cancer and adjacent normal tissues was analyzed with bioinformatics tool. The differential expressed lncRNAs between liver cancer and adjacent normal tissues were analyzed with bioinformatics tool. Cell viability and proliferation was tested by CCK8 and Ki67, respectively. Apoptosis of liver cancer cells was tested by flow cytometry. Gene and protein expressions in liver cancer cells were measured by qRT-PCR and western blot, respectively. LINC01234 was found to be negatively correlated with the survival rate of patients with liver cancer. Moreover, knockdown of LINC01234 significantly suppressed the proliferation and invasion of liver cancer cells via inducing the apoptosis. Meanwhile, miR-513a-5p was sponged by LINC01234, and USP4 was found to be a direct target of miR-513a-5p. In addition, LINC01234 knockdown inhibited the tumorigenesis of liver cancer via inactivating TGF-β signaling. Furthermore, silencing of LINC01234 notably inhibited the tumor growth of liver cancer Downregulation of LINC01234 could inhibit the tumorigenesis of liver cancer via mediation of miR-513a-5p/USP4/TGF-β axis. Thus, LINC01234 might serve as a new target for the treatment of liver cancer.

Sections du résumé

BACKGROUND BACKGROUND
Liver cancer is a frequent malignancy with poor prognosis and high mortality all over the world. It has been reported many lncRNAs could modulate the tumorigenesis of liver cancer. To identify novel potential targets for liver cancer, the differential expressed lncRNAs between liver cancer and adjacent normal tissues was analyzed with bioinformatics tool.
METHODS METHODS
The differential expressed lncRNAs between liver cancer and adjacent normal tissues were analyzed with bioinformatics tool. Cell viability and proliferation was tested by CCK8 and Ki67, respectively. Apoptosis of liver cancer cells was tested by flow cytometry. Gene and protein expressions in liver cancer cells were measured by qRT-PCR and western blot, respectively.
RESULTS RESULTS
LINC01234 was found to be negatively correlated with the survival rate of patients with liver cancer. Moreover, knockdown of LINC01234 significantly suppressed the proliferation and invasion of liver cancer cells via inducing the apoptosis. Meanwhile, miR-513a-5p was sponged by LINC01234, and USP4 was found to be a direct target of miR-513a-5p. In addition, LINC01234 knockdown inhibited the tumorigenesis of liver cancer via inactivating TGF-β signaling. Furthermore, silencing of LINC01234 notably inhibited the tumor growth of liver cancer
CONCLUSION CONCLUSIONS
Downregulation of LINC01234 could inhibit the tumorigenesis of liver cancer via mediation of miR-513a-5p/USP4/TGF-β axis. Thus, LINC01234 might serve as a new target for the treatment of liver cancer.

Identifiants

DOI: 10.3389/fonc.2020.571565 PMID: 33178601 PMC: PMC7597595
pubmed: 33178601
doi: 10.3389/fonc.2020.571565
pmc: PMC7597595
doi:

Types de publication

Journal Article

Langues

eng

Pagination

571565

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2020 Xu, Li, Song, Wang, Li, Xu, Liang, Deng, Wang and Liu.

Références

Cell Oncol (Dordr). 2020 Jun;43(3):377-394
pubmed: 32130660
Oncogene. 2019 Aug;38(32):6065-6081
pubmed: 31273338
Sci Rep. 2020 Jan 16;10(1):521
pubmed: 31949263
Chin Med J (Engl). 2020 Jun 5;133(11):1298-1303
pubmed: 32452895
Mol Cell Biochem. 2020 Dec;475(1-2):79-91
pubmed: 32761300
FEBS Open Bio. 2020 May;10(5):817-826
pubmed: 32150666
Aging (Albany NY). 2020 Jan 17;12(2):1047-1086
pubmed: 31956102
Front Oncol. 2020 Oct 16;10:571565
pubmed: 33178601
J Invest Dermatol. 2020 Oct;140(10):2060-2072.e6
pubmed: 32142796
J Cell Mol Med. 2020 Apr;24(8):4557-4568
pubmed: 32150333
FASEB J. 2020 Sep;34(9):11546-11561
pubmed: 32767602
Oncogene. 2020 Mar;39(11):2408-2423
pubmed: 31959898
Oncotarget. 2014 May 15;5(9):2792-806
pubmed: 24798342
J Cell Physiol. 2021 Mar;236(3):2051-2057
pubmed: 32743796
Neoplasia. 2020 Apr;22(4):163-178
pubmed: 32143140
J Cell Mol Med. 2020 Sep;24(18):10935-10945
pubmed: 32767729
J Cell Biol. 1994 Dec;127(6 Pt 2):2021-36
pubmed: 7806579
Life Sci. 2020 May 15;249:117503
pubmed: 32142767
Cancer Cell Int. 2020 Aug 5;20:371
pubmed: 32774165
Mol Ther Nucleic Acids. 2019 Sep 6;17:347-361
pubmed: 31302495
Biosci Rep. 2020 Jan 31;40(1):
pubmed: 31967298
J Hepatol. 2021 Jan;74(1):122-134
pubmed: 32738449
Biochim Biophys Acta Mol Basis Dis. 2020 Jul 1;1866(7):165757
pubmed: 32147422
Cell Physiol Biochem. 2019;53(1):157-171
pubmed: 31251006
IUBMB Life. 2020 Jul;72(7):1460-1467
pubmed: 32150331
Aging (Albany NY). 2020 Jun 3;12(11):10544-10555
pubmed: 32493835
Mol Med Rep. 2019 Aug;20(2):1429-1435
pubmed: 31173246
BMC Cell Biol. 2015 Mar 06;16:7
pubmed: 25885904
Cancer Manag Res. 2020 Jul 06;12:5395-5408
pubmed: 32753957
Aging (Albany NY). 2018 Oct 18;10(10):2783-2799
pubmed: 30335615
Aging (Albany NY). 2020 Jul 21;12(14):14141-14156
pubmed: 32692718
Exp Cell Res. 2020 May 1;390(1):111939
pubmed: 32142853
Medicine (Baltimore). 2020 Aug 7;99(32):e21652
pubmed: 32769936
Hepatol Res. 2020 Jun;50(6):726-740
pubmed: 32039538
Aging (Albany NY). 2020 Aug 3;12(15):15546-15555
pubmed: 32756004
Biosci Rep. 2020 Apr 30;40(4):
pubmed: 32149330
Biomed Pharmacother. 2020 Oct;130:110568
pubmed: 32745911
Curr Pharm Des. 2020;26(4):415-428
pubmed: 31939724
Chem Res Toxicol. 2020 Jun 15;33(6):1356-1363
pubmed: 31942800
J Exp Clin Cancer Res. 2020 Aug 4;39(1):150
pubmed: 32746934
Oncol Rep. 2020 Feb;43(2):718-726
pubmed: 31894346
Stem Cell Res Ther. 2020 Jan 3;11(1):8
pubmed: 31900225
Int J Cancer. 2020 Feb 15;146(4):1139-1151
pubmed: 31219614
J Hematol Oncol. 2020 Jan 8;13(1):5
pubmed: 31915027

Auteurs

Wen Xu (W)

State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.

Kesang Li (K)

Department of Hematology and Oncology, Hwa Mei Hospital, Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China.
Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo, China.

Changfeng Song (C)

State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.

Xiaotong Wang (X)

State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.

Yueqi Li (Y)

State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.

Baixue Xu (B)

State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.

Xin Liang (X)

State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.

Wanli Deng (W)

Department of Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Junqing Wang (J)

Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Jianwen Liu (J)

State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.

Classifications MeSH